MedTrace Logo

Odronextamab in Low Tumor Volume Advanced FL

NCT07128641 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2026-03-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of treating previously untreated Follicular Lymphoma (FL) with odronextamab.

The name of the study drug in this research study is:

-Odronextamab (a type of monoclonal antibody)

Conditions

Interventions

BIOLOGICAL

Odronextamab

A CD20xCD3 bispecific monoclonal antibody, glass vials, via intravenous (into the vein) infusion per protocol.

Sponsors & Collaborators

Principal Investigators

  • Gottfried Von Keudell, MD, PhD · Beth Israel Deaconess Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-08
Primary Completion
2027-01-02
Completion
2028-01-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07128641 on ClinicalTrials.gov